FGFR fusions in the driver's seat.
FGFR fusions in the driver's seat.
复制标题
DOI：
10.1158/2159-8290.cd-13-0185
复制
发表时间：
2013-06
期刊：
影响因子：
28.2
通讯作者：
Bivona TG
中科院分区：
文献类型：
--
作者：
Sabnis AJ;Bivona TG
通过临床深度测序方案，Wu及其同事在多种癌症中鉴定了多种FGFR融合蛋白。FGFR的药理学抑制抑制了FGFR融合阳性肿瘤模型的生长，表明这些FGFR融合是致癌驱动因子，并突出了简化的临床测序工作在人类肿瘤中鉴定新的可操作驱动致癌蛋白的效用。
Through a clinical deep sequencing protocol, Wu and colleagues have identified multiple FGFR fusion proteins in diverse cancers. Pharmacologic inhibition of FGFR suppressed the growth of FGFR fusion positive tumor models, suggesting that these FGFR fusions are oncogenic drivers and highlighting the utility of streamlined clinical sequencing efforts to identify novel, actionable driver oncoproteins in human tumors.